Centering discussion on a patient case of metastatic non–small cell lung cancer, expert Sandip P. Patel, MD, provides insight into updated research and treatment strategies with immunotherapeutic and targeted agents.
EP. 1: Case Overview: A 62-Year-Old Woman with Squamous Histology and PD-L1 Negative mNSCLC
Expert oncologist Sandip Patel, MD, discusses treatment decisions for a 62-year-old female with squamous cell lung cancer, highlighting the use of CTLA4 and PD1 inhibitors based on subgroup analysis.
EP. 2: Challenges in Non-Small Cell Lung Cancer Treatment: Addressing Unmet Needs
Key insight into ongoing challenges and unmet needs in non-small cell lung cancer treatment, including specific patient populations and potential solutions through clinical trials.
EP. 3: PD-L1 Testing and Its Role in Lung Cancer Treatment Decision-Making
Expert perspectives on the significance and limitations of PD-L1 testing in non-small cell lung cancer and the importance of integrating genomic characterization for informed treatment choices.
EP. 4: Long-Term Immunotherapy Updates in Lung Cancer: Survival Beyond Treatment
A concise review of five-year updates from pivotal immunotherapy studies in lung cancer, highlighting the durability of responses and treatment options for high-risk disease
EP. 5: Long-Term Benefits of Chemoimmunotherapy in Lung Cancer: Updates and Considerations
Sandip Patel, MD, discusses the durability of immunotherapy responses, updated survival data from clinical trials, and considerations for patients in the metastatic lung cancer setting.
EP. 6: Tailoring Lung Cancer Treatment: Balancing Immunotherapy, Chemotherapy, and Targeted Therapies
Insight into key patient characteristics and considerations in determining the optimal approach for treating metastatic non-small cell lung cancer, including the role of chemotherapy, immunotherapy, and targeted therapy.
EP. 7: Bright Future of Lung Cancer Research: Targeted Therapies and Immunotherapy Advancements
Expert Sandip Patel, MD, looks toward the promising future of lung cancer research, including targeted therapies, novel immunotherapy approaches, and the importance of biomarkers in guiding treatment decisions.
2 Clarke Drive Cranbury, NJ 08512